Treating diabetic retinopathy by inhibiting growth factor pathways

Current Opinion in Investigational Drugs

Volumn 10, Issue 4, 2009, Pages 327-335

  Frank, Robert N ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bevacizumab; controlled clinical trial; mAb; macular edema; pegaptanib; ranibizumab; steroid; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BEVACIZUMAB; BEVASIRANIB; ERYTHROPOIETIN; GROWTH FACTOR; GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; MIDOSTAURIN; OCTREOTIDE; OMEGA 3 FATTY ACID; PEGAPTANIB; PEGVISOMANT; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RAPAMYCIN; RUBOXISTAURIN; SOMATOMEDIN C; STEROID; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; LOADING DRUG DOSE; MEDICAL RESEARCH; NONHUMAN; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; THERAPY EFFECT;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETIC RETINOPATHY; ERYTHROPOIETIN; EYE PROTEINS; FATTY ACIDS, OMEGA-6; HORMONE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN-LIKE GROWTH FACTOR I; MACULAR EDEMA; NERVE GROWTH FACTORS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RECEPTORS, SOMATOTROPIN; SERPINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63849248396     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol (1984) 102(4):520-526.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol (1984) 102(4):527-532.
3. Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S: Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol (2006) 141(3):446-455.
4. Klein R, Klein BE, Moss SE, Davis MD, DeMets D: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology (1984) 91(12):1464-1474.
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology (1995) 102(1):7-16.
6. Michaelson IC: The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK (1948) 68:137-180.
7. Frank RN: Etiologic mechanisms in diabetic retinopathy. In: Retina. 4th Edition. Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP (Eds), Elsevier, London, UK (2006):1240-1270.
8. Campochiaro PA: Ocular versus extraocular neovascularization: Mirror images or vague resemblances. Invest Ophthalmol Vis Sci (2006) 47(2):462-474.
9. Frank RN: Medical progress: Diabetic retinopathy. N Engl J Med (2004) 350(1):48-58.
10. Smith LE: Through the eyes of a child. Understanding retinopathy through ROP. The Friedenwald Lecture. Invest Ophthalmol Vis Sci (2008) 49(12):5177-5182.
11. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 331(22):1480-1487.
12. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 118(4):445-450.
13. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219(4587):983-985.
14. 14. Senger DR, Perruzzi CA, Feder J, Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 46(11):5629-5632.
15. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE et al: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes (1997) 46(9):1473-1480.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 351(27):2805-2816.
17. Starita C, Patel M, Katz B, Adamis AP: Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol (2007) 39:122-148.
18. Eyetech Pharmaceuticals Inc: Macugen (pegaptanib sodium injection) shows positive visual and anatomical outcomes in a phase II trial for patients with diabetic macular edema (DME). Press release (2004): 03 May.
19. Eyetech Pharmaceuticals Inc: Eyetech announces enrollment of the first patient in a phase III clinical trial of Macugen (pegaptanib sodium injection) in diabetic macular edema (DME) and diabetic retinopathy. Press release (2005): 17 October.
20. Eyetech Pharmaceuticals Inc: Eyetech announces launch date for Macugen (pegaptanib sodium injection). Press release (2005): 20 January.
21. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 57(20):4593-4599.
22. Baca M, Presta LG, O'Connor SJ, Wells JA: Antibody humanization using monovalent phage display. J Biol Chem (1997) 272(16):10678- 10684.
23. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol (2002) 29(6 Suppl 16):10-14.
24. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N: Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophthalmol Vis Sci (2008) 49(2):522-527.
25. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 355(14):1432-1444.
26. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 355(14):1419-1431.
27. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology (2006) 113(10):1706-1712.
28. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 142(6):961-969.
29. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK et al: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina (2006) 26(5):495-511.
30. Miller JW: Using a drug before the risks and benefits are known from a phase 3 clinical trial. Arch Ophthalmol (2006) 124(7):1029- 1031.
31. Packer S, Jampol LM: An ethical view of the ranibizumab and bevacizumab controversy. Arch Ophthalmol (2008) 126(2):286.
32. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ et al: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology (2007) 114(10): 1860-1867.
33. Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ: Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis (2008) 14:997-1005.
34. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis (2003) 9:210-216.
35. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B et al: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 452(7187):591-597.
36. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA: VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 195(2):241-248.
37. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA: A phase I trial of an IVadministered vascular endothelial growth factor Trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 113(9):1522.e1-1522.e14.
38. Stewart MW, Rosenfeld PJ: Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol (2008) 92(5):667-668.
39. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest (1996) 98(9):2018-2026.
40. Ishii H, Koya D, King GL: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med (1997) 76(1):21-31.
41. Frank RN: New medical therapies for diabetic retinopathy: Protein kinase C inhibitors. Am J Ophthalmol (2002) 133(5):693-698.
42. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE: Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology (2006) 113(12):2221-2230.
43. PKC-DMES Study Group: Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol (2007) 125(3):318-324.
44. Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H: Dose-and timedependent pharmacokinetics of midostaurin in patients with diabetes mellitus. J Clin Pharmacol (2008) 48(6):763-775.
45. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T: PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des (2000) 15(1):17-28.
46. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA: Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol (2000) 156(2):697-707.
47. Adamis AP: Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol (2002) 86(4):363-365.
48. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology (1991) 98(5):757-765.
49. Kern TS, Engerman RL: Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes (2001) 50(7):1636-1642.
50. Li WW, Casey R, Gonzalez EM, Folkman J: Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci (1991) 32(11): 2898-2905.
51. Crum R, Szabo S, Folkman J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science (1985) 230(4732):1375-1378.
52. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology (2008) 115(9):1447- 1449.
53. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE: Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci (2006) 47(11):4935-4941.
54. Abraham RT, Wiederrecht GJ: Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 14:483-510.
55. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG: Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol (1995) 154(2):922-927.
56. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y: Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci (2005) 46(2):454-460.
57. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J: Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis (2004) 10:964-972.
58. Poulsen JE: Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes (1953) 2(1):7-12.
59. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology (2001) 108(12):2266-2272.
60. Palii SS, Caballero S Jr, Shapiro G, Grant MB: Medical treatment of diabetic retinopathy with somatostatin analogs. Expert Opin Investig Drugs (2007) 16(1):73-82.
61. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med (1999) 5(12):1390-1395.
62. Hellström A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M, Svensson E, Smith L, Weinberger D, Albertsson Wikland K et al: IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab (2002) 87(7):3413-3416.
63. Chen J, Smith LE: Retinopathy of prematurity. Angiogenesis (2007) 10(2):133-140.
64. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulindependent diabetes. N Engl J Med (1993) 329(14):977-986.
65. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulindependent diabetes mellitus: The Oslo study. Br Med J (1985) 290(6471):811-815.
66. Chantelau E, Kohner EM: Why some cases of retinopathy worsen when diabetic control improves. Br Med J (1997) 315(7116):1105- 1106.
67. Becerra SP, Fariss RN, Wu YQ, Montuenga LM, Wong P, Pfeffer BA: Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: Apical secretion and distribution. Exp Eye Res (2004) 78(2):223-234.
68. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J: Pigment epithelium-derived factor: Neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA (1993) 90(4):1526-1530.
69. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science (1999) 285(5425):245-248.
70. Stellmach V, Crawford SE, Zhou W, Bouck N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA (2001) 98(5):2593-2597.
71. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J: Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett (2001) 489(2-3):270-276.
72. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh EJ, Yang HS, Cingolani C, Lai H, Wei L, Campochiaro PA: Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther (2003) 10(8):637-646.
73. Saishin Y, Silva RL, Saishin Y, Kachi S, Aslam S, Gong YY, Lai H, Carrion M, Harris B, Hamilton M, Wei L et al: Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum Gene Ther (2005) 16(4):473-478.
74. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R et al: Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum Gene Ther (2006) 17(2):167-176.
75. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 119(10):1417-1436.
76. Madsen-Bouterse SA, Kowluru RA: Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Rev Endocrine Metab Disorders (2008) 9(4):315-327.
77. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Liou GI, Caldwell RW: Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets (2005) 6(4):511-524.
78. Kunisaki M, Bursell SE, Clermont AC, Ishii H, Ballas 78. LM, Jirousek MR, Umeda F, Nawata H, King GL: Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol (1995) 269(2 Pt 1):E239-E246.
79. Millen AE, Gruber M, Klein R, Klein BE, Palta M, Mares JA: Relations of serum ascorbic acid and a-tocopherol to diabetic retinopathy in the Third National Health and Nutrition Examination Survey. Am J Epidemiol (2003) 158(3):225-233.
80. Millen AE, Klein R, Folsom AR, Stevens J, Palta M, Mares JA: Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr (2004) 79(5):865-873.
81. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A et al: Increased dietary intake of omega-3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med (2007) 13(7):868-873.
82. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T et al: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med (2005) 353(8):782-792.
83. Hernändez C, Fonollosa A, Garcïa-Ramïrez M, Higuera M, Catalän R, Miralles A, Garcïa-Arumï J, Simö R: Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care (2006) 29(9):2028-2033.
84. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, Buehler J et al: Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA (2008) 105(19):6998-7003.
85. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull SB, Boright AP, Paterson AD: Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: The DCCT/EDIC genetics study. Diabetes (2007) 56(8):2161-2168.
86. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP et al: Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med (2007) 13(2):181-188.
87. Greenberg DA, Jin K: From angiogenesis to neuropathology. Nature (2005) 438(7070):954-959.
88. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 171(1):53-67.
89. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N: Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology (2005) 112(6):1048-1053.
90. Roodhart JM, Langenberg MN, Witteveen E, Voest EE: The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol (2008) 3(2):132-143.
91. The Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology (1981) 88(7):583-600.
92. Ferris FL 3rd: How effective are treatments for diabetic retinopathy? J Am Med Assoc (1993) 269(10):1290-1291.
93. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema, Early Treatment Diabetic Retinopathy Study report no. 1. Arch Ophthalmol (1985) 103(12):1796-1806.